AbstrAct
Objectives Although a significant proportion of patients with cyanotic congenital heart disease are thrombocytopaenic, its prevalence and clinical significance in adults with Eisenmenger syndrome (ES) is not well studied. Accordingly, we examined the relationship of thrombocytopaenia and mean platelet volume (MPV) to bleeding or thrombotic complications and survival in a contemporary cohort of patients with ES, including patients with Down syndrome. Methods Demographics, laboratory and clinical data were analysed from 226 patients with ES under active follow-up over 11 years. results Age at baseline was 34.6±11.4 years and 34.1% were men. Mean platelet count and MPV were 152.6±73.3×10
9 /L and 9.6±1.2 fL, respectively. A strong inverse correlation was found between platelet count and haemoglobin concentration and MPV. During the study, there were 39 deaths, and 21 thrombotic and 43 bleeding events. On univariate Cox regression analysis, patients with a platelet count <100×10 9 /L had a twofold increased mortality (HR 2.10, 95% CI 1.10 to 4.01, p=0.024). Platelet count was not associated with an increased risk of thrombosis. However, there was a threefold increased thrombotic risk with MPV >9.5 fL (HR 3.50, 95% CI 1.28 to 9.54, p=0.015). Patients with either severe secondary erythrocytosis (>220g/L) or anaemia (<130g/L) were at higher risk of thrombotic events (HR 3.93, 95% CI 1.60 to 9.67, p=0.003; and HR 4.75, 95% CI 1.03 to 21.84, p=0.045, respectively). conclusions Thrombocytopaenia significantly increased the risk of mortality in ES. Furthermore, raised MPV, severe secondary erythrocytosis and anaemia, but not platelet count, were associated with an increased risk of thrombotic events in our adult cohort.
IntrOductIOn
Eisenmenger syndrome (ES) is a pathophysiological condition that starts with a large central left-toright shunt causing a progressive increase in pulmonary vascular resistance, with reversal of shunting and resultant hypoxaemia. 1 Patients with ES are at increased risk of death and other major complications such as bleeding and thrombosis, 2 3 posing ongoing management challenges. 4 5 Although many patients with cyanotic congenital heart disease present with thrombocytopaenia, 6 its prevalence and clinical implications in ES have not been fully examined. 7 8 The role of platelets is essential for primary haemostasis and repair of the endothelium. Furthermore, platelets also participate actively in the development of acute coronary syndromes and contribute to cerebrovascular events through the formation of atherosclerotic plaques. 9 Activated platelets release a large number of substances that are crucial mediators of coagulation, inflammation, thrombosis and atherosclerosis. 10 Increased platelet volume is associated with increased platelet reactivity, shortened bleeding time 11 and increased platelet aggregation ex vivo. 12 Several studies have shown that an increased mean platelet volume (MPV) is present in patients with coronary artery disease, 13 14 and MPV is an independent risk factor for stroke and myocardial infarction in this population, 15 but its impact in patients with cyanotic congenital heart disease remains unknown.
The aim of our study was to assess the relationship between thrombocytopaenia and MPV to bleeding and thrombotic complications, as well as survival, in a large and contemporary cohort of patients with ES.
MethOds
Data were collected retrospectively on all patients with ES under active follow-up at the Royal Brompton Hospital between June 2005 and July 2016. Demographic data, full blood count (haemoglobin (Hb), platelet count and MPV), iron studies and clinical outcome were obtained and analysed. Cardiac lesions were classified into three categories according to shunt type: pretricuspid (ie, atrial septal defect), post-tricuspid (ie, ventricular septal defect or patent ductus arteriosus) and complex anatomy (other shunt lesions including atrioventricular septal defects, common arterial trunk or combined pretricuspid and post-tricuspid defects). ES was defined as pulmonary hypertension with cyanosis in the presence of a large non-restrictive intracardiac or extracardiac defect. 16 Cyanosis was defined as baseline oxygen saturation of ≤90% at rest. Thrombotic or haemorrhagic complications were identified from thorough review of designated clinical records for all patients.
Venous samples were taken into 4 mL Vacutainer K2E tubes containing 7.2 mg EDTA (Vacutainer K2E; Becton Dickinson, Oxford, UK) for Full Blood ORIgInAL RESEARCH ARTICLE Platelet count and mean platelet volume predict outcome in adults with Eisenmenger syndrome congenital heart disease Count (FBC) analysis and/or silica-coated coagulation vacutainer (BD Vacutainer SST II Advance, Cheshire, UK) using a 21-gauge butterfly needle for iron studies and liver function tests. FBC was analysed in DxH 800 analyser (Beckman Coulter UK, Buckinghamshire, UK) within 1 hour of collection of the samples. Normal ranges for Hb, platelets and MPV were 115-151 g/L, 147−397×10 9 /L and 7.4-11.5 fL, respectively. Thrombocytopaenia was defined as platelet count less than 150×10 9 /L. Iron deficiency was defined as ferritin <20 μg/L or transferrin saturation <20%. Serum ferritin was performed in Beckman Access 2 Automated immunoassay analysers (Beckman Coulter, Brea, California, USA), and serum iron and transferrin saturation was performed in Beckman AU680 autoanalyser (Beckman Coulter). Oxygen saturation was assessed by pulse oximetry.
statistical analysis
Data were summarised as mean±SD for continuous variables and number (%) for categorical variables. Comparison of continuous variables between groups was performed using non-parametric Wilcoxon rank-sum test or Kruskal-Wallis test, and categorical variables were compared using Fisher's exact test. The relation between clinical parameters and outcome measures was assessed using univariable and multivariable Cox proportional hazard regression analyses, using the date of blood tests as the start (baseline) date. The proportional hazards assumption was tested using scaled Schoenfeld residuals. The functional form of the relation between platelet count, MPV and Hb was assessed using the functions termplot and pspline. In addition, as comparison groups differed in baseline characteristics, we performed propensity score adjustment: we constructed two logistic regression models with platelet count <100 and MPV >9.5 as dependent variables, respectively. Independent variables included age, sex, presence of Down syndrome (DS), anatomic diagnosis (ES vs other), resting oxygen saturations, aspirin or warfarin use, and pulmonary arterial hypertension (PAH) therapies at baseline. Based on these models, propensity scores were estimated for each patient and the patients were matched using nearest neighbour matching (2:1 for the platelet analysis and 1:1 for the MPV analysis, package MatchIt). The relation between platelet count and MPV to survival and thrombosis was thereafter assessed in the matched populations. Matched pairs were used as strata in the Cox model once adequate balance was ensured. Statistical analyses were carried out using R V.3.3.0 (R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; http://www. R-project. org/). For all analyses, a two-tailed p value <0.05 was used as the criterion for statistical significance.
results

Patient population
In total, 226 adults with ES were included in the study. The mean age at baseline was 34.6±11.4 years, and 34.1% were men. Demographics and baseline characteristics are shown in table 1. The mean oxygen saturation was 84.8%±6.6%. Most patients had a complex anatomy (50.0%), followed by post-tricuspid shunt (43.4%) and pretricuspid shunt (6.6%).
Fifty-six (24.8%) patients were on PAH advanced therapies at baseline, whereas another 132 (58.4%) patients were started on advanced therapy during the study follow-up. Among patients on PAH advanced therapies at any point during the study, 144 (63.7%) were on phosphodiesterase type 5 inhibitors and 108 (47.8%) on endothelin receptor antagonists (ERA) (table 1); 64 patients (28.3%) were on combination therapy. (table 1) . However, only few (4.9%) patients with ES had an abnormal MPV (>11.5 fL). There was an inverse correlation between platelet count and both Hb concentration (r=0.66, p<0.0001) and MPV (r=0.46, p<0.0001) ( figure 1A,B) . A weaker correlation was found between MPV and Hb concentration (r=0.33, p<0.0001; figure 1C ). Patients with lower resting oxygen saturations had higher Hb levels (r=0.37, p<0.0001; figure 1D ) as expected.
Iron deficiency was present in 45.4% of patients, who had significantly lower Hb compared with the remainder (184±30.5 g/L vs 201.9±28.1 g/L; p<0.0001). Patients with iron deficiency also had higher platelet counts (169.8±79.8×10 9 /L vs 139.6±64.6×10 9 /L; p=0.003) but did not differ on MPV (p=0.15).
down syndrome
DS was present in 99 (43.8%) patients; 71.7% had complex anatomy and 27.3% a post-tricuspid shunt. Patients with DS were younger, less likely to be on warfarin or to have received iron supplementation, but had higher ferritin and transferrin saturations, and higher Hb levels (p=0.0008, table 1). While there was no difference in the proportion of patients on PAH therapies at baseline or follow-up between DS and non-DS subjects, the DS group was less likely to receive an ERA during the follow-up (p<0.0001).
Platelet count was significantly lower in patients with DS, but they had similar MPV to patients with no DS. An inverse correlation was observed between platelet count and both Hb concentration (r=0.57, p<0.0001) and MPV (r=0.5, p<0.0001) in the DS subgroup ( figure 1A,B) . In contrast, a weaker correlation was found between MPV and Hb concentration (r=0.25, p=0.01; figure 1C) . Thus, these correlations of haematological parameters in patients with DS followed the same pattern as of the total population.
Mortality and predictors of bleeding and thrombosis
During a median follow-up of 8.1 years (1681.6 patient-years), 39 patients died. On univariate Cox regression analysis, patients with a platelet count of <100×10 9 /L had a twofold increased mortality (HR 2.10, 95% CI 1.10 to 4.01, p=0.024; figure 2A) , and this remained after propensity score matching to account for differences between the two groups (HR in the matched population 2.39, 95% CI 1.04 to 5.53, p=0.04). Other univariable predictors of death included age (HR per 10-year increase 1.34, 95% CI 1.05 to 1.73, p=0.02) and resting oxygen saturations (HR per 10% decrease 1.09, 95% CI 1.03 to 1.15, p=0.001). There was no relation between MPV and death in this population.
During the follow-up period, there were 21 thrombotic and 43 bleeding events (table 2). Thrombotic events included eight cases of stroke, four transient ischaemic attacks, one episode of acute pulmonary embolism and one peripheral thrombosis (in a patient later diagnosed with coexistent Behcet syndrome). There were an additional seven patients with previously unknown congenital heart disease 'in situ' pulmonary thrombosis established by CT scan. The eight strokes were all confirmed on CT scan or MRI and most were relatively transient, with neurological symptoms resolving within a few days. Only one patient aged 72 years suffered severe residual haemiparesis with significant limitation of daily activities, whereas a second 53-year-old patient had a slower recovery after the cerebrovascular accident. The patient, who suffered an acute pulmonary embolism, had a history of recurrent deep vein thrombosis.
Patients with a very high (>220 g/L) or very low (<130 g/L) Hb concentration were at increased risk of thrombotic events (HR 3.93, 95% CI 1.60 to 9.67, p=0.003; and HR 4.75, 95% CI 1.03 to 21.84, p=0.045, respectively), whereas platelet count did not relate to thrombosis. The cut-offs of 220 g/L and 130 g/L are derived from our termplot analysis, which plotted Hb concentration against the risk of death (data not shown). In contrast, an MPV >9.5 fL was associated with a threefold increased risk of thrombotic events (HR 3.50, 95% CI 1.28 to 9.54, p=0.015; figure 2B), and this remained even after adjustment for baseline differences between MPV groups using propensity score matching (HR 5.50, 95% CI 1.22 to 24.81, p=0.027). On multivariate stepwise Cox analysis, both Hb (used as a categorical variable, above 220 and below 130 g/L) and an MPV >9.5 fL remained in the model (HR for MPV >9.5 fL 2.96, 95% CI 1.03 to 8.5, p=0.045). When excluding pulmonary artery thrombosis from the analysis (n=14 events), an Hb <130 g/L was predictive of thrombotic events (HR 7.19, 95% CI 1.47 to 35.16, p=0.015), whereas an Hb >220 g/dL and MPV >9.5 fL were not (p=0.06 and p=0.24, respectively).
Bleeding events included 21 cases of haemoptysis, 6 of menorrhagia, 5 cases of gastrointestinal (GI) bleeding, 4 of epistaxis, 3 of cerebral haemorrhage, 2 of haematuria, 1 of iliopsoas haematoma and 1 of severe spontaneous bruising. Ten bleeding episodes were considered major according to the International Society on Thrombosis and Haemostasis definition for non-surgical sites (ie, fall in Hb level of 20 g/L or more, or requiring transfusion of two or more units of whole blood or red cells) 17 : three haemoptysis episodes were associated with admission, with one leading to bronchial artery embolisation. Two patients with GI bleeding were admitted too, one required several blood transfusions. Two further patients with menorrhagia required acute admission, whereas a third underwent endometrial ablation. One patient with severe epistaxis required a semiurgent cauterisation procedure. Finally, the patient presenting with an iliopsoas haematoma required admission and developed significant femoral nerve injury. Before these major bleeding events, 6 of the 10 patients were on warfarin, whereas 1 was on aspirin. No relation was found between Hb concentration, platelet count or MPV and major bleeding.
dIscussIOn
Our data show an inverse relation between platelet count, Hb concentration and MPV in patients with ES. Platelet count but not MPV was predictive of mortality in our cohort. An MPV >9.5 fL and severe secondary erythrocytosis or anaemia congenital heart disease were associated with an increased risk of thrombosis, but not bleeding events. Chronic cyanosis typically leads to an increase in erythropoietin production and an isolated rise in the red blood cell count (secondary erythrocytosis), 18 enhancing oxygen tissue delivery. Not surprisingly, the vast majority (90%) of our patients with ES had secondary erythrocytosis with elevated Hb concentration. There is a close and inverse relationship between the degree of secondary erythrocytosis and the severity of cyanosis in iron-replete patients ( figure 1D) . 19 Thrombocytopaenia coincided with a high Hb concentration in our population ( figure 1A) , likely reflecting the severity of cyanosis and right-to-left shunting. In this situation, it is hypothesised that the right-to-left shunt delivers whole megakaryocytes into the systemic circulation, bypassing the lungs where megakaryocytic cytoplasm is normally fragmented into platelets, thus limiting platelet production. 20 In fact, the larger the right-to-left shunt, the lower the systemic arterial oxygen saturation, the higher the Hb and the lower the platelet count. 21 It is, thus, not a surprise that a low platelet count is associated with a higher mortality in patients with cyanotic congenital heart disease and may reflect the severity of cyanosis and its systemic effects. 7 While bleeding and thrombotic complications are frequent in patients with cyanotic congenital heart disease, there is no clear relation between these complications and platelet count. 8 Major bleeding is not uncommon in ES and can become life-threatening, but bleeding does not appear to be the means by which the platelet count relates to mortality in this population. A low platelet count, thus, appears to be a surrogate of advanced multisystem disease, indirectly, yet strongly, related to mortality.
Thrombotic complications were relatively common in our population, with an incidence of 1.2% per patient-year, while the incidence of acute pulmonary embolism was very low at 0.06% per patient-year. The prevalence of in situ pulmonary thrombosis was lower (3%) than previously reported at 21%. 22 However, as radiation may have an adverse effect and renal dysfunction is not uncommon in ES, 23 we do not routinely perform CT pulmonary angiograms in all patients; thus, in situ thrombosis is likely to be under-reported in this study. More importantly, we found a low incidence at 0.12% per patient-year of significant cerebrovascular events with residual neurological deficit in our population, despite the obvious increased risk of paradoxical emboli in adults with cyanotic congenital heart disease. 24 This may support the practice of not routinely anticoagulating all patients with ES, who are also at risk of major bleeding. There are, indeed, no clinical data to support routine anticoagulation or antiplatelet therapy in this population in the absence of other clinical indications, such as atrial flutter/fibrillation, recurrent thromboembolic events (in the absence of iron deficiency or dehydration), pulmonary artery thrombosis or pulmonary emboli, or in the presence of mechanical prosthetic valves.
MPV reflects platelet size and is a marker of platelet function; an elevated MPV has been associated with higher aggregating activity ex vivo. Several studies have reported an increased MPV in other patient groups, that is, coronary artery disease, which in turn relates to adverse outcome (higher risk of myocardial infarction). 15 Larger platelets appear to be more active and more thrombogenic, with an increased aggregating capacity compared with normal size platelets. In our study, few (4.9%) patients with ES had an abnormal MPV, but when this exceeded 9.5 fL, it was associated with a threefold increased risk of thrombosis (figure 2B). MPV remained in the model predicting thrombosis together with Hb, suggesting that platelet activation plays an independent role in thrombosis in ES beyond secondary erythrocytosis and its possible effect on blood viscosity.
Bleeding events were relatively uncommon in our patients, with an incidence of 2.6% per patient-year. Haemoptysis was the most common complication among them, occurring at 1.2 per 100 patient-years; in most cases, haemoptysis was minor and self-limiting. Major episodes of haemoptysis requiring admission or bronchial artery embolisation occurred in 3 out of 21 patients. The fact that no association was found between bleeding events and platelet count, Hb concentration or MPV suggests that compensatory mechanisms may be in place in ES reducing the risk of bleeding, which in itself needs further exploration. These patients may have raised fibrinogen, factor VIII or Von Willebrand factor antigen and activity due to underlying chronic disease, which compensate for the bleeding risk associated with thrombocytopaenia. Jensen et al 25 reported a hypocoagulable state in patients with cyanotic congenital heart disease, mainly related to impaired fibrinogen function, which in turn was independent of platelet count. However, the fact that of 6 out of 10 patients who had a 'major' bleeding event were on anticoagulation treatment and only 24.8% of the total population were on warfarin may suggest that anticoagulation therapy may have had a bearing on bleeding.
Chromosome 21 is thought to play an important role in haematopoiesis and leucemogenesis. 26 Patients with DS are known to have a relatively high incidence of haematological disorders and leukaemia, including transient abnormal myelopoiesis or megakaryocytic dysregulation. 27 Our data suggest that the mechanism behind lower platelet counts in patients with DS compared with their non-Down counterparts is not related to abnormalities in the platelet maturation process; indeed, there was no difference in MPV between the two groups. Bone marrow abnormalities are known to be associated with DS, and we submit that the low platelet counts seen in patients with DS may be related to bone marrow deficiency. However, despite a high prevalence of thrombocytopaenia, major bleeding episodes were very infrequent in patients with DS, observed in only 2 out of 100 patients. This supports our current practice of active surveillance of patients with DS with thrombocytopaenia, only intervening when bleeding occurs. Indeed, venesection is rarely used to boost platelet count and may be considered in conjunction with platelet transfusion in patients requiring dental or other surgery.
Iron supplementation is, nowadays, recommended by experts for iron-deficient patients with ES, especially those in whom Hb concentration is far lower than anticipated based on their oxygen saturations. 28 Iron deficiency at baseline was common in this study, present in 45.4% of patients, more so than previous studies. 29 However, cut-off values for the definition of iron deficiency vary significantly between studies, and evidence is currently lacking on the type and duration of optimal iron supplementation in this setting. Iron supplementation invariably leads to an increase in Hb concentration, which for some may raise concerns about potential thrombotic events, even though the latter were uncommon in our study. Moreover, the associated drop in platelet count is feared to promote bleeding, even though no relation between platelet count and bleeding events was found in this study. Iron deficiency is associated with an increase mortality in ES, 30 and while the therapeutic dilemma of how aggressively to treat it remains, the risk of promoting thrombotic or bleeding events by doing so is low, supporting our current approach of being proactive in screening and treating iron deficiency in ES.
congenital heart disease limitations
The main limitation of our study is its retrospective nature. We report patients from a single tertiary centre who, we believe, are representative of current ES practice. We do not include other parameters of risk stratification in this population, such as braintype natriuretic peptide (BNP) and echocardiographic indices. Data on platelet function were not available, but MPV is felt to be a surrogate for this. Larger prospective studies are needed to validate our data, shed additional light on the mechanisms behind thrombotic and bleeding events in ES and identify strategies for minimising relevant risks. The number of events and design of the study did not allow us to create a complex Cox model accounting for multiple time-varying covariates, such as PAH therapies or serial changes in haematological and other clinical variables. Larger studies or registries are required to clarify this important point.
cOnclusIOns
Thrombocytopaenia significantly increased the risk of mortality in ES. Furthermore, raised MPV, severe secondary erythrocytosis and anaemia, but not platelet count, were associated with an increased risk of thrombotic events in our adult cohort. We submit these haematological parameters should be incorporated in the risk stratification algorithm of these patients, while future studies may shed additional light on how they relate to ES outcomes.
Key messages
What is already known on this subject? A significant number of patients with cyanotic congenital heart disease are thrombocytopaenic. Moreover, patients with Eisenmenger syndrome (ES) are at increased risk of death and other major complications such as bleeding and thrombosis, posing ongoing management challenges.
What might this study add?
Thrombocytopaenia significantly increases the risk of mortality in adults with ES. Moreover, raised mean platelet volume, severe secondary erythrocytosis and/or anaemia, but not platelet count, are associated with an increased risk of thrombotic events in ES.
how might this impact on clinical practice? Platelet count and mean platelet volume, and/or severe erythrocytosis or anaemia, should be incorporated in the risk stratification algorithm of ES. Our data suggest the need for close surveillance of haematological parameters in ES and call for further mechanistic studies in the field.
